Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.61 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.61 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407357 | 0.89 | ROCK2 (0.63) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL4578714 | 0.88 | CLK2 (0.65) | MEN1KMT2AP2RX7MAP4K4CLK2 | |
| SCHEMBL5417979 | 0.86 | CNR1 (0.64) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL17776529 | 0.85 | ROCK2 (0.71) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL2571077 | 0.84 | ROCK2 (0.74) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL5413020 | 0.84 | ROCK2 (0.65) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL23075124 | 0.83 | CNR1 (0.69) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL5411112 | 0.83 | P2RX7 (0.65) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL20673098 | 0.83 | ROCK2 (0.68) | ROCK2ROCK1MEN1KMT2AP2RX7 | |
| SCHEMBL2572294 | 0.82 | ROCK2 (0.66) | ROCK2ROCK1MEN1KMT2AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| CN-100413860-C | piperidine derivatives as NMDA receptor antagonists | HUNGARY GIREL GYOGYSZERGYAR (HU) | 2008-08-27 | — | — | CN | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1567525-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| CN-1556805-A | piperidine derivatives as NMDA receptor antagonists | ������ҩ������˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | ROCK2 4291/4885ROCK1 3751/4885MEN1 2584/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885MEN1 2593/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ROCK2 4762/4885ROCK1 4724/4885MEN1 3200/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ROCK2 4761/4885ROCK1 4757/4885MEN1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.